Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Wants Authority To Mandate Minor Post-Approval Quality Changes

Executive Summary

Legislative proposal in FY 2020 budget request wouldn't necessarily reduce number of complete response letters, but ability to require reports and postmarket changes on quality issues might eventually create more flexibility during initial product reviews.

You may also be interested in...



Biosimilar Pathway Would Disappear If ACA Repealed, Gottlieb Says

Asked during Senate hearing whether the 351(k) pathway would be repealed along with the rest of the ACA under a pending lawsuit, the outgoing commissioner acknowledged that it would,  but said he hoped Congress would create it again.

Pfizer Must Correct Data Integrity Problems Seen At India Plant Globally, FDA Says

US FDA warning letter instructed Pfizer to implement a global corrective and preventive action plan to address widespread data integrity problems. While the impact of the warning letter on the site is expected to be minimal due to its closure, the global impact on the company’s sterile drug operations could be significant.

FDA Reassures Patients Of Generic Drug Quality Amid Questions In Media Analysis

Commissioner Scott Gottlieb and CDER Director Janet Woodcock say in joint statement that patients can be confident generics are safe and effective and recent media reports misinterpreted inspection and other data when suggesting the contrary.

Related Content

Topics

UsernamePublicRestriction

Register

PS124951

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel